Person:
YILDIZ, PELİN

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
PELİN
Last Name
YILDIZ
Name
Email Address
Birth Date

Filters

2020 - 20222
Reset filters

Settings

Author: ONSUN, NAHIDE × End date: 2022 × Start date: 2020 × Type: Article ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Challenges in early diagnosis of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma: a case series of four patients.
    (2020-08-01T00:00:00Z) Akaslan, TÇ; Dizman, D; Emiroğlu, N; Tosuner, Z; Çetin, G; Demirkesen, C; ONSUN, NAHIDE; YILDIZ, PELİN; ÇETİN, GÜVEN
    Background: Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AECTCL) is a rare and aggressive lymphoma characterised by ulcerated lesions and a poor prognosis. Objectives: To present a case series of four previously misdiagnosed AECTCL patients and discuss the importance of early diagnosis. Materials and methods: All patients in this study were identified from the database of the Dermatology Department of the Medical School of Bezmialem Vakif University, based on clinical and histopathological diagnosis of AECTCL between 2010 and 2018. Results: AECTCL cases may mimic many benign dermatoses and accurate diagnosis may be delayed. Conclusion: Because of its poor prognosis, early diagnosis of AECTCL may be helpful in improving the likelihood of patient survival, but further study is needed to address the challenges in diagnosing this rare and aggressive lymphoma.
  • Thumbnail Image
    PublicationOpen Access
    Clinical and histopathological improvement of scleromyxedema-induced microstomia after hyaluronidase injection
    (2022-05-01T00:00:00Z) AKASLAN, TAHSİN ÇAĞDAŞ; YILDIZ, PELİN; ONSUN, Nahide; AKASLAN, TAHSİN ÇAĞDAŞ; YILDIZ, PELİN; ONSUN, NAHIDE
    Introduction Scleromyxedema is a rare primary cutaneous mucinosis characterized by numerous firm, waxy, confluent papules. Recently, intravenous immunoglobulin (IVIG) is accepted by many authors as the first-line treatment option for severe cases. We report a 69-year-old male patient who has been suffering from scleromyxedema, with reduced mouth opening. He has been on a high-dose IVIG regime for 5 years. Methods The patient stated that he had difficulty in wearing and removing his dentures because of reduced mouth opening lately. Before considering to add any other immunosuppressants to his regime, we injected 1500 IU of hyaluronidase in total in one session periorally. The patient has been told open his mouth maximum and photographs have been taken before injections and after one month. We used a photo measurement application when evaluating microstomia to increase accuracy. We also took punch biopsies in order to evaluate effect of hyaluronidase histopathologically before and one month after injections. Results One month later, he was able to reattach and remove his dentures without adding any adjuvant immunosuppressants other than hyaluronidase. Mouth opening was increased in measurements and histopathologically, mucin deposition, fibroblastic proliferation, and perivascular lymphocytic infiltration were decreased. Conclusions We think hyaluronidase is a safe, easily accessible, and effective treatment option for microstomia caused by scleromyxedema.